Roivant Sciences
ROIV
293 hedge funds and large institutions have $5.77B invested in Roivant Sciences in 2024 Q2 according to their latest regulatory filings, with 64 funds opening new positions, 102 increasing their positions, 83 reducing their positions, and 26 closing their positions.
146% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 26
23% more repeat investments, than reductions
Existing positions increased: 102 | Existing positions reduced: 83
13% more funds holding
Funds holding: 259 → 293 (+34)
7.91% more ownership
Funds ownership: 65.97% → 73.88% (+7.9%)
3% more capital invested
Capital invested by funds: $5.6B → $5.77B (+$165M)
0% more funds holding in top 10
Funds holding in top 10: 19 → 19 (0)
12% less call options, than puts
Call options by funds: $14.4M | Put options by funds: $16.4M
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$123M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$59.2M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$32.9M |
| 4 |
TCA
Troluce Capital Advisors
Dorado,
Puerto Rico
|
+$32.3M |
| 5 |
Goldman Sachs
New York
|
+$29.6M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$69.1M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$50.6M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$49M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$34.8M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
-$27.2M |
ROIV Hedge Fund Activity: Q2 2024 in Review
293 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Roivant Sciences (ROIV) for Q2 2024, worth a combined $5.77B — up 2.9% from $5.6B a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new ROIV positions and 26 closed out — a net gain of 38 holders — while 102 added to existing stakes and 83 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $123M. The largest seller was Morgan Stanley, cutting an estimated $69.1M.
- 293 institutional investors held Roivant Sciences (ROIV) as of Q2 2024, up from 259 in Q1 2024.
- Funds reported $5.77B of Roivant Sciences stock for Q2 2024, up 2.9% quarter-over-quarter.
- 64 funds opened new Roivant Sciences positions in Q2 2024 and 26 closed out, a net change of +38 holders.
- The largest Roivant Sciences buyer in Q2 2024 was Fidelity Investments, an estimated $123M added.
- The largest Roivant Sciences seller in Q2 2024 was Morgan Stanley, an estimated $69.1M sold.
Based on aggregated 13F filings for Q2 2024.